[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @bio_clouseau M M posts on X about $tsro, $mrk, $gsk, $srpt the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::43475268/interactions)  - X Week XXXXXX +266% - X Month XXXXXX -XX% - X Months XXXXXXX +30% - X Year XXXXXXXXX +48% ### Mentions: X [#](/creator/twitter::43475268/posts_active)  - X Week X -XX% - X Month XX -XX% - X Months XXX +7.20% - X Year XXX +219% ### Followers: XXXXXX [#](/creator/twitter::43475268/followers)  - X Week XXXXXX +0.27% - X Month XXXXXX +0.52% - X Months XXXXXX +2% - X Year XXXXXX +4.90% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::43475268/influencer_rank)  ### Social Influence [#](/creator/twitter::43475268/influence) --- **Social category influence** [stocks](/list/stocks) XXXX% **Social topic influence** [$tsro](/topic/$tsro) 5.66%, [$mrk](/topic/$mrk) 3.77%, [$gsk](/topic/$gsk) 3.77%, [$srpt](/topic/$srpt) 1.89%, [$gild](/topic/$gild) 1.89%, [$bmy](/topic/$bmy) 1.89%, [$ptgx](/topic/$ptgx) 1.89%, [$clvs](/topic/$clvs) 1.89%, [$pbyi](/topic/$pbyi) 1.89%, [$vinc](/topic/$vinc) XXXX% **Top accounts mentioned or mentioned by** [@bertrandbio](/creator/undefined) [@byamybrown](/creator/undefined) [@jq1234t](/creator/undefined) [@bymadeleinea](/creator/undefined) [@jacobplieth](/creator/undefined) [@syinvesting](/creator/undefined) [@gcbioinv](/creator/undefined) [@davidc85097716](/creator/undefined) [@pilldipp](/creator/undefined) [@joserestonva](/creator/undefined) [@maximus_holla](/creator/undefined) [@marketwirenews](/creator/undefined) [@biopharmaddict](/creator/undefined) [@monkechevarria](/creator/undefined) [@garbageman1985](/creator/undefined) **Top assets mentioned** [Merck & Co., Inc. (MRK)](/topic/$mrk) [GSK plc (GSK)](/topic/$gsk) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Protagonist Therapeutics, Inc (PTGX)](/topic/$ptgx) ### Top Social Posts [#](/creator/twitter::43475268/posts) --- Top posts by engagements in the last XX hours "This seems like a steal considering $MRK paid lanova close to 600M in in November XX for the pd-1/vegf and 2.7B bio bucks remaining. Though thats only if one thinks there's a very good chance of achieving even 1/3 of the biobucks"  [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1945155481317646830) 2025-07-15 16:16:20 UTC 19.6K followers, 4567 engagements "$SRPT gets a platform tech designation on 6/4 for its AAVrh74 viral vector for LGMD 2E/R4 which seems to indicate the viral vector is "well understood" and "utilized by more than one drug without an adverse effect on quality manufacturing or safety". A little more than a month later FDA asks to voluntarily stop all shipments and issues a statement saying Sarepta "refused" the request and also pulls the platform designation just handed a month earlier. A lot of fingers being pointed at SRPT (rightfully)for being far from transparant but the FDA is not without fault either with its new found"  [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1946508655873995232) 2025-07-19 09:53:22 UTC 19.6K followers, 29.8K engagements "Interesting comment since $GSK has been mainly spending on late oncology drugs like $TSRO. And most of their other deals have been less extravagant than say $GILD $MRK $BMY. Quite difficult to restart an oncology pipeline after predecessor sells off most of it"  [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1406935087938146305) 2021-06-21 11:20:39 UTC 19.6K followers, XX engagements "$PTGX Protagonist unveils 'triple-G' obesity pill but human trials are nearly a year away -"  [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1940033780141396181) 2025-07-01 13:04:31 UTC 19.6K followers, 3919 engagements "Probably a few exceptions like $TSRO $SRRA where smaller biotechs have made a very good ROI on oncology discards from larger biotechs/pharma but seem to be more examples like $VINC $PBYI $CLVS where that strategy has failed miserably"  [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1783812752626049070) 2024-04-26 10:57:56 UTC 19.6K followers, 3930 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
M posts on X about $tsro, $mrk, $gsk, $srpt the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Social category influence stocks XXXX%
Social topic influence $tsro 5.66%, $mrk 3.77%, $gsk 3.77%, $srpt 1.89%, $gild 1.89%, $bmy 1.89%, $ptgx 1.89%, $clvs 1.89%, $pbyi 1.89%, $vinc XXXX%
Top accounts mentioned or mentioned by @bertrandbio @byamybrown @jq1234t @bymadeleinea @jacobplieth @syinvesting @gcbioinv @davidc85097716 @pilldipp @joserestonva @maximus_holla @marketwirenews @biopharmaddict @monkechevarria @garbageman1985
Top assets mentioned Merck & Co., Inc. (MRK) GSK plc (GSK) Sarepta Therapeutics, Inc. (SRPT) Gilead Sciences, Inc. (GILD) Bristol-Myers Squibb Co (BMY) Protagonist Therapeutics, Inc (PTGX)
Top posts by engagements in the last XX hours
"This seems like a steal considering $MRK paid lanova close to 600M in in November XX for the pd-1/vegf and 2.7B bio bucks remaining. Though thats only if one thinks there's a very good chance of achieving even 1/3 of the biobucks" @bio_clouseau on X 2025-07-15 16:16:20 UTC 19.6K followers, 4567 engagements
"$SRPT gets a platform tech designation on 6/4 for its AAVrh74 viral vector for LGMD 2E/R4 which seems to indicate the viral vector is "well understood" and "utilized by more than one drug without an adverse effect on quality manufacturing or safety". A little more than a month later FDA asks to voluntarily stop all shipments and issues a statement saying Sarepta "refused" the request and also pulls the platform designation just handed a month earlier. A lot of fingers being pointed at SRPT (rightfully)for being far from transparant but the FDA is not without fault either with its new found" @bio_clouseau on X 2025-07-19 09:53:22 UTC 19.6K followers, 29.8K engagements
"Interesting comment since $GSK has been mainly spending on late oncology drugs like $TSRO. And most of their other deals have been less extravagant than say $GILD $MRK $BMY. Quite difficult to restart an oncology pipeline after predecessor sells off most of it" @bio_clouseau on X 2021-06-21 11:20:39 UTC 19.6K followers, XX engagements
"$PTGX Protagonist unveils 'triple-G' obesity pill but human trials are nearly a year away -" @bio_clouseau on X 2025-07-01 13:04:31 UTC 19.6K followers, 3919 engagements
"Probably a few exceptions like $TSRO $SRRA where smaller biotechs have made a very good ROI on oncology discards from larger biotechs/pharma but seem to be more examples like $VINC $PBYI $CLVS where that strategy has failed miserably" @bio_clouseau on X 2024-04-26 10:57:56 UTC 19.6K followers, 3930 engagements
/creator/twitter::bio_clouseau